Navigation Links
Rutgers Genetics receives $7.8 million for autism research
Date:9/5/2007

The Simons Foundation, through its Autism Research Initiative, has signed a $7.8 million, two-year contract with the Rutgers University Cell and DNA Repository (RUCDR) to establish a collection of DNA samples for autism studies. The samples will be collected from 2,000 families that have a single autistic child.

The Simons Simplex Collection, as this project is known, will constitute the core resource for a new and different line of research into the genetics of autism, said RUCDR Scientific Director Jay Tischfield, who is also the Duncan and Nancy MacMillan Professor of Genetics at Rutgers. We will be looking not only at autism that is passed from generation to generation, but also at autism that derives from sporadic genetic changes that may occur within one generation. It is now recognized that such sporadic mutations may account for a large fraction of autism cases.

Blood samples from the 8,000 participating family members will be collected at 11 centers around the United States and shipped to Rutgers for processing into DNA and cell lines that will then be preserved and stored in vaults of liquid nitrogen. Autism researchers will be able to access these genetic specimens through the auspices of the Simons Foundation.

We are proud to have been chosen by the Simons Foundation to construct and maintain this unique and unprecedented resource, a tool that can help unlock some of the mysteries of autism, said Richard L. McCormick, president of Rutgers, The State University of New Jersey. The opportunity to contribute to this initiative is due in great measure to the leadership position that Rutgers scientists have achieved in the field of medical genetics.

Autism is a disorder that manifests early in life and has no known cure. It is tied to a childs early brain development and is usually diagnosed in the first three years of life.

Autistic children typically have difficulties with behavior, social interaction an
'/>"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers, the State University of New Jersey
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Rutgers to lead $52.7 million protein research program
2. Rutgers researchers scientifically link dancing ability to mate quality
3. Rutgers researchers find fat gene
4. FDA approves first medical device using rutgers biomaterial
5. Mosaic mouse technique offers a powerful new tool to study diseases and genetics
6. Genetics links whale to two different ocean basins
7. New technique could alter field of mouse genetics
8. Scientists unpick genetics of first 15 minutes of life
9. New research examines genetics of successful aging
10. Alcoholism, smoking and genetics among Plains American Indians
11. New research examines genetics of successful aging

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ists are revealing the genetic instructions inside... maize, has one of the most complex sequences of D...ison genomicist David Schwartz, who was one of mor...Science . , "The maize genome is a true maze fu...oubled would-be sequencers for years," says Schwar...
(Date:11/19/2009)... 1 = more than 2: The offspring of two inbred stra...Characterizing the gene-level variability that lea...d vigor, could boost our ability to custom-tailor ...ntent for human consumption or high glucose conten...released DNA sequence of the common corn strain B7...
(Date:11/19/2009)...etic diversity in maize, also known as corn, resea...gene map that should pave the way to significant i...ood, fuel, animal feed and fiber around the world.... as a haplotype map, charts genetic diversity and ... of maize. The research team, led by U.S. Departme...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President International Sales 5593 1University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President International Sales 5593 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President International Sales 5593 3BrainCells Inc Broadens Scientific Advisory Board Adding Drs Edward Scolnick and David Holtzman 5590 1BrainCells Inc Broadens Scientific Advisory Board Adding Drs Edward Scolnick and David Holtzman 5590 2BrainCells Inc Broadens Scientific Advisory Board Adding Drs Edward Scolnick and David Holtzman 5590 3Enhanced Food Safety and Systems Interoperability the Themes of Food Traceability Interoperability Summit 2010 5587 1Enhanced Food Safety and Systems Interoperability the Themes of Food Traceability Interoperability Summit 2010 5587 2
...ns when no medical necessity exists - Florida, Ne...ington, Florida increase most , The number of pre...sarean section (C-section) rose by 36.6 percent fr...ay by HealthGrades, the leading provider of indepe...e variation from state to state in the rate of the...
...al waste, placental tissue could feasibly provide ...l to treat diseases and regenerate tissues as thei...cells, suggests a University of Pittsburgh study t...able now as an early online publication in Stem Ce...mnion, or the outer membrane of the amniotic sac, ...
... the risk of mother-to-child transmission of hepat...ublished in the December 1 issue of The Journal of... study found that infant girls are twice as likely...ide new information with which to counsel pregnant...new studies expand upon preliminary data from smal...
Other Biology News:'Patient-choice' C-section rate rises 36%: HealthGrades study 2'Patient-choice' C-section rate rises 36%: HealthGrades study 3Discarded placentas deliver researchers promising cells similar to embryonic stem cells 2Discarded placentas deliver researchers promising cells similar to embryonic stem cells 3Discarded placentas deliver researchers promising cells similar to embryonic stem cells 4Studies clarify risk factors for mother-to-child transmission of hepatitis C virus 2
(Date:11/18/2009)... -- Marrone Bio Innovations (MBI), a leader in the...ffective and environmentally responsible pest mana...an IC20 company by the Investors, Circle, the Unit...ting group. ,, Companies named to the IC20 exce...all stakeholders, including investors, the environ...
(Date:11/18/2009)...ind explosive materials and persons who have been ...tional Institute of Standards and Technology (NIST...curity, has developed a new certified reference ma...ace Particulate Explosives. Compatible with field ...ful in calibrating, testing and developing standar...
(Date:11/18/2009)...e developing new sensors to detect chemical agents...ainst the threat of terrorist attacks. , The dev...idual or crime scene to gather a sample which is t...ect the presence of chemicals within seconds. This... response to terrorist threats. , The scanning ...
(Date:11/18/2009)...alysis combined with Bio-Rad,s Biotechnology E...ovide state-of-the-art solutions to biotechnology ...wire/ -- Vernier Software & Technology, a prov...nd software and Bio-Rad Laboratories, Inc., a mult...ence research and clinical diagnostics products th...
Breaking Biology Technology:Marrone Bio Innovations Named an IC20 Company 2New NIST trace explosives standard slated for homeland security duty 2New technology detects chemical weapons in seconds 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2
...ce to $0.64 - $0.67 from Prior Range of ... EPS Guidance of $0.90 - $1.10 for 2009 and $1.50 ...PITTSBURGH, Oct. 30 Mylan Inc. (NYSE: MYL ),toda...d nine months ended,Sept. 30, 2008., Financial Hi....52 for the three and nine,months ended Sept. 30, ...
...Inc. (Nasdaq:,INSM), a developer of follow-on biol...ts for the third quarter and nine-months ended Sep... Follow-on Biologics Program -- Received app... Healthcare products Regulatory Agency to init...pany,s second follow-on biologic ("FOB") ...
...oratories Inc., a,specialty pharmaceutical and dia...nd Trademark Office (USPTO) has issued two separat...) Thiopurine Metabolites, a,diagnostic test that e...iopurines to reach and maintain desired therapeuti...he claims in U.S. Patent Nos. 7,425,546 and,7,429,...
Other Biology Technology:Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 2Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 4Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 5Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 6Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 7Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 8Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 9Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 10Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing 2
...Kit contains all reagents necessary to efficiently...tic lineage, as determined by staining for mineral...essary reagents and a protocol for quantifying ost...uct is useful for studying the effects of growth f...
...arch: Developed for a wide range of bioanalytical ... in Luminescence Spectroscopy • Automated acc...ic gratings for reduced stray light • Versati...non lamp reduces photo bleaching • Large conv...
...tent-pending Formula Predictor software takes adva... pattern verification, and unique fragment-ion fil...ect formula for unknown components. Traditional ...ss spec data often depend on very high mass accura...
PerkinElmer Spectrum Beer's Law QUANT Quantitative Software, Floppy Disk from PerkinElmer
Biology Products: